Answers are grounded in this paper and cite their sources.
AIM: To develop an anti-drug antibody (ADA) assay for a bispecific antibody (bsAb) we will refer to as Drug-1, and to quantify the ADAs against each specific fragment antigen-binding (Fab) site of Drug-1. MATERIALS AND METHODS: Here we use two additional unlabeled monoclonal antibodies (mAbs) Drug-2 & Drug-3 in an ADA confirmation assay format. Drugs-2 & -3 have the same targets as the two Fabs of Drug-1, facilitating our aim to measure and quantify the anti-drug Abs against each specific Fab of Drug-1 by signal inhibition. RESULTS AND CONCLUSION: By using the combination of a screening and a dual confirmation assay format, we were able to accurately quantify the ADAs against each specific Fab of the bsAb Drug-1.
No takes yet. Share an insight, caveat, or question.
Rowe et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: